Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Empagliflozin is a more cost-effective treatment than oral semaglutide at preventing cardiovascular death in patients with type 2 diabetes . Have a read: https://www.m3india.in/contents/clinical_news/empagliflozin-is-a-more-cost-effective-treatment?utm_campaign=unset&utm_medium=share&utm_source=ref_wa